The incidence of hypothyroidism in case of monotherapy is highest for PD-1 inhibitors, followed by PD-L1 and CTLA-4 block, and combined ICIs treatment is responsible of a remarkably higher incidence of hypothyroidism, hyperthyroidism, hypophysitis, and primary adrenal insufficiency when compared to chemotherapy alone [75]. Here, PDCD1 is linked to hypophysitis.